VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Core Viewpoint - VolitionRx Limited is proposing an underwritten public offering of its common stock and accompanying purchase warrants, with a potential additional 15% option for the underwriter [1][2]. Group 1: Offering Details - The offering will be made under a "shelf" registration statement previously filed with the SEC, and the final terms will depend on market conditions [3]. - Newbridge Securities Corporation is acting as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions [2]. Group 3: Company Overview - Volition is a multinational company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancers and conditions associated with NETosis [5][6]. - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [7].